News

BioSpace5m

Lilly’s Hotly Anticipated Oral Weight Loss Drug Delivers Lukewarm Results in Phase III

Lilly’s orforglipron cut body weight as expected in the Phase III ATTAIN-1 trial, but to a lesser extent than rival Novo ...
Fierce Biotech55m

Eli Lilly shakes up pain pipeline as part of quarterly R&D clearout

Lilly paid $47.5 million upfront to license the non-opioid pain drug candidate CNTX-0290 from Centrexion in 2019. The SSTR4 ...

Eli Lilly to sell troubled N.J. pharmaceutical plant, but says jobs are safe. Here’s why.

Eli Lilly and Company has confirmed it’s selling its 25,000-square-foot manufacturing site in Branchburg. The decision was ...

Stock Movers: Intel, PTON, Ely Lilly

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Eli Lilly beats earnings for second quarter on strong GLP-1 sales, stock dives on GLP-1 pill trial results

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
The Daily Reporter14h

Eli Lilly and Co. could get $100 million in state tax credits

Eli Lilly is eligible for 100M in tax credits to expand its Pleasant Prairie facility, adding 750 jobs and boosting Wisconsin ...

Jim Cramer Shows Concerns That Eli Lilly “Might Be a Little Diluted”

Eli Lilly and Company (NYSE: LLY) is one of the stocks in Jim Cramer’s game plan for this week. Cramer highlighted that his ...

Eli Lilly Earnings, Fed Speakers, Bank of England Rate Decision: Still to Come This Week

Earnings season marches on, with Eli Lilly among the big names yet to report this week. President Trump has said he will name replacements this week for Federal Reserve governor Adriana Kugler and [Bu ...